Aryee D N, Simonitsch I, Mosberger I, Kos K, Mann G, Schlögl E, Pötschger U, Gadner H, Radaszkiewicz T, Kovar H
Children's Cancer Research Institute, St Anna Kinderspital, Vienna, Austria.
Br J Cancer. 1996 Dec;74(11):1693-8. doi: 10.1038/bjc.1996.616.
The nm23-H1 gene is a putative metastasis-suppressor gene encoding a 17 kDa protein with nucleoside diphosphate kinase activity. Expression of nm23-H1/NDPK-A correlates inversely with the metastasising potential of some human tumours and experimental animal cells. No nm23 expression studies exist for human malignant lymphomas so far. In this study, we examined nm23-H1 expression by Northern and immunohistochemical analysis in 106 primary lymphoma samples from patients with Hodgkin's disease (HD) (n = 15), high-grade non-Hodgkin's lymphoma (NHL) from different lineages (n = 71) and low-grade NHL (n = 20). Both inter- and intra-subtype variations in nm23-H1/NDPK-A expression levels were demonstrated by all disease subtypes. Besides this heterogeneity, a general trend towards highly malignant samples expressing higher nm23-H1/NDPK-A, levels than the low-grade lymphomas was observed. Both adult and childhood HD and high-grade NHL samples exhibited significantly higher NDPK-A expression than the low-grade NHL found only in adults. High nm23-H1/NDPK-A levels in lymphoma samples did not always reflect proliferative activity of tumour cells as monitored by Ki-67 antigen staining. Fifty samples were further investigated for possible mutations in the nm23-H1 coding sequence by means of reverse transcriptase-polymerase chain reaction (RT-PCR) and single-strand conformation polymorphism (SSCP) analysis. No mutation was found by this screening. Our results suggest a role for nm23-H1 expression in the disease aggressiveness of lymphomas.
nm23-H1基因是一种假定的转移抑制基因,编码一种具有核苷二磷酸激酶活性的17 kDa蛋白质。nm23-H1/NDPK-A的表达与某些人类肿瘤和实验动物细胞的转移潜能呈负相关。迄今为止,尚无关于人类恶性淋巴瘤的nm23表达研究。在本研究中,我们通过Northern印迹和免疫组织化学分析检测了106例原发性淋巴瘤样本中nm23-H1的表达,这些样本来自霍奇金病(HD)患者(n = 15)、不同谱系的高级别非霍奇金淋巴瘤(NHL)(n = 71)和低级别NHL(n = 20)。所有疾病亚型均显示出nm23-H1/NDPK-A表达水平的亚型间和亚型内差异。除了这种异质性外,还观察到一个总体趋势,即高恶性样本比低级别淋巴瘤表达更高水平的nm23-H1/NDPK-A。成人和儿童HD以及高级别NHL样本的NDPK-A表达均显著高于仅在成人中发现的低级别NHL。淋巴瘤样本中nm23-H1/NDPK-A的高水平并不总是反映通过Ki-67抗原染色监测的肿瘤细胞增殖活性。通过逆转录聚合酶链反应(RT-PCR)和单链构象多态性(SSCP)分析,对50个样本进一步研究了nm23-H1编码序列中可能的突变。通过该筛查未发现突变。我们的结果表明nm23-H1表达在淋巴瘤的疾病侵袭性中起作用。